336 related articles for article (PubMed ID: 25043171)
1. The future of JAK inhibition in myelofibrosis and beyond.
Mascarenhas JO; Cross NC; Mesa RA
Blood Rev; 2014 Sep; 28(5):189-96. PubMed ID: 25043171
[TBL] [Abstract][Full Text] [Related]
2. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
Pardanani A; Tefferi A
Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
[TBL] [Abstract][Full Text] [Related]
3. 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
Assi R; Verstovsek S; Daver N
Curr Opin Hematol; 2017 Mar; 24(2):115-124. PubMed ID: 28072602
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C; Tam CS; Verstovsek S
Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
[TBL] [Abstract][Full Text] [Related]
5. [Novel therapeutics in myeloproliferative neoplasms: beyond JAK inhibitors].
Edahiro Y
Rinsho Ketsueki; 2023; 64(9):970-980. PubMed ID: 37793873
[TBL] [Abstract][Full Text] [Related]
6. Emerging targeted therapies in myelofibrosis.
Barosi G
Expert Rev Hematol; 2012 Jun; 5(3):313-24. PubMed ID: 22780211
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
Alchalby H; Kröger N
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Rosenthal A; Mesa RA
Expert Opin Pharmacother; 2014 Jun; 15(9):1265-76. PubMed ID: 24766055
[TBL] [Abstract][Full Text] [Related]
10. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutics in myeloproliferative neoplasms.
Venugopal S; Mascarenhas J
J Hematol Oncol; 2020 Dec; 13(1):162. PubMed ID: 33267911
[TBL] [Abstract][Full Text] [Related]
12. Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
Bose P; Verstovsek S
J Natl Compr Canc Netw; 2016 Dec; 14(12):1613-1624. PubMed ID: 27956543
[TBL] [Abstract][Full Text] [Related]
13. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
Pardanani A; Vannucchi AM; Passamonti F; Cervantes F; Barbui T; Tefferi A
Leukemia; 2011 Feb; 25(2):218-25. PubMed ID: 21079613
[TBL] [Abstract][Full Text] [Related]
14. Kinase signaling and targeted therapy for primary myelofibrosis.
Yang Q; Crispino JD; Wen QJ
Exp Hematol; 2017 Apr; 48():32-38. PubMed ID: 28043820
[TBL] [Abstract][Full Text] [Related]
15. Reducing symptom burden in patients with myeloproliferative neoplasms in the era of Janus kinase inhibitors.
Mesa RA; Scherber RM; Geyer HL
Leuk Lymphoma; 2015 Jul; 56(7):1989-99. PubMed ID: 25644746
[TBL] [Abstract][Full Text] [Related]
16. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition.
Komrokji R; Verstovsek S
Expert Rev Hematol; 2012 Dec; 5(6):631-41. PubMed ID: 23216593
[TBL] [Abstract][Full Text] [Related]
17. The use of JAK inhibitors for low-risk myelofibrosis.
Alimam S; McLornan D; Harrison C
Expert Rev Hematol; 2015 Oct; 8(5):551-3. PubMed ID: 26343888
[TBL] [Abstract][Full Text] [Related]
18. How we manage JAK inhibition in allogeneic transplantation for myelofibrosis.
Ballinger TJ; Savani BN; Gupta V; Kroger N; Mohty M
Eur J Haematol; 2015 Feb; 94(2):115-9. PubMed ID: 25256963
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths.
Tefferi A
Blood; 2012 Mar; 119(12):2721-30. PubMed ID: 22279053
[TBL] [Abstract][Full Text] [Related]
20. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
